TCT 2023: Six-Month Clinical Data from DESyne® BDS Plus Randomized Controlled Trial (RCT) Support Safety and Effectiveness of World’s First Site-Specific Antithrombotic Drug Therapy
Elixir Medical announced positive six-month clinical data from the DESyne BDS Plus Randomized Controlled Trial (RCT) evaluating DESyne BDS Plus versus a second-generation, durable polymer drug-eluting stent (DES).
Randomized Clinical Dataset Featuring World’s First Triple Drug-Eluting Coronary Implant Eluting Two Anticoagulants and Sirolimus At TCT 2023
Elixir Medical will present primary endpoint and 6-month data from its DESyne BDS Plus Randomized Clinical Trial (RCT), a prospective, multicenter, single-blind study, as part of The Innovation Program at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco
Job Post Template
Major Duties and Responsibilities Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla […]
Elixir Medical Completes Enrollment of INFINITY-SWEDEHEART Clinical Trial
The trial, which includes 2,400 patients from 20 sites across Sweden, compares DynamX Bioadaptor to Resolute Onyx.
DynamX Bioadaptor Restores Rotational Motion and Vessel Stress Reduction in New Study
A study in the latest issue of Cardiovascular Revascularization Medicines hows that the DynamX™ Coronary Bioadaptor System, when uncaged, enabled rotational motion similar to natural vessels.
Elixir Medical Expands Bioadaptor Randomized Controlled Trial of DynamX Coronary Bioadaptor System
MILPITAS, Calif. – April 22, 2021 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the BIOADAPTOR randomized controlled trial (RCT) is expanding to centers in Belgium and Germany. The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology. The BIOADAPTOR RCT is […]
Elixir Medical Announces Commencement Of Infinity-Swedeheart Randomized Controlled Trial of DynamX Coronary Bioadaptor System
2,400-Patient Trial Utilizes Globally-Respected SWEDEHEART Registry Database in Randomized Study of First Metallic Device Treating Coronary Artery Disease That Adapts to Vessel Physiology MILPITAS, Calif. – March 16, 2021 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced commencement of the INFINITY-SWEDEHEART randomized controlled trial (RCT) of the DynamX™ Coronary Bioadaptor System, the first metallic […]